Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 9/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7957164 | 0.83 | DRD2 (0.56) | CCR1DRD2 | |
| SCHEMBL7960074 | 0.83 | DRD2 (0.62) | CCR1ADRA1ADRD2 | |
| SCHEMBL7963517 | 0.83 | CCR1 (0.54) | CCR1KDM4EKMT2AADRA1ADRD2 | |
| SCHEMBL7960233 | 0.83 | CCR1 (0.54) | CCR1KMT2AADRA1ADRD2ADRA1D | |
| SCHEMBL7949619 | 0.83 | DRD2 (0.53) | CCR1ADRA1ADRD2ADRA2AADRA2B | |
| SCHEMBL7949042 | 0.82 | CCR1 (0.52) | CCR1DRD2 | |
| SCHEMBL7957456 | 0.82 | CCR1 (0.56) | CCR1KMT2AADRA1ADRD2ADRA2A | |
| SCHEMBL7963903 | 0.82 | DRD2 (0.50) | CCR1DRD2 | |
| SCHEMBL7959852 | 0.81 | KDM4E (0.47) | CCR1KDM4EADRA1ADRD2OPRL1 | |
| SCHEMBL8568579 | 0.79 | OPRM1 (0.58) | CCR1DRD2OPRL1ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6187774-B1 | N-PIPERAZINYLALKYLINDAZOLE DERIVATIVES; PSYCHOLOGICAL DISORDERS, SCHIZOPHRENIA; SIDE EFFECT REDUCTION | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2001-02-13 | — | — | US | disclosed |
| EP-0885883-A1 | FUSED HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-12-23 | — | — | EP | disclosed |